Ki67 targeted strategies for cancer therapy

被引：224
|
作者：
Yang, C. [1 ]
Zhang, J. [1 ]
Ding, M. [1 ,2 ]
Xu, K. [1 ,2 ]
Li, L. [1 ]
Mao, L. [1 ,2 ]
Zheng, J. [1 ]
机构：
[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China
[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China
来源：
CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期
关键词：
Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;
D O I：
10.1007/s12094-017-1774-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.
引用
收藏
页码：570 / 575
页数：6
相关论文
共 50 条
  • [31] Chromogranin A Expression and Ki67 Index in Residual Rectal Cancer Treated with Preoperative Therapy
    Vecchio, F. M.
    Arena, V.
    Barba, M. C.
    Castri, F.
    Doglietto, G. B.
    Coco, C.
    Crucitti, A.
    Ricci, R.
    Corbosiero, A.
    Valerio, L.
    Valentini, V.
    MODERN PATHOLOGY, 2011, 24 : 171A - 172A
  • [32] A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study
    Bahaddin, Mowafak Masoud
    ANNALS OF MEDICINE AND SURGERY, 2020, 60 : 232 - 235
  • [33] Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer
    Stalhammar, Gustav
    Robertson, Stephanie
    Wedlund, Lena
    Lippert, Michael
    Rantalainen, Mattias
    Bergh, Jonas
    Hartman, Johan
    HISTOPATHOLOGY, 2018, 72 (06) : 974 - 989
  • [34] Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
    Boyaci, Ceren
    Sun, Wenwen
    Robertson, Stephanie
    Acs, Balazs
    Hartman, Johan
    BIOMOLECULES, 2021, 11 (11)
  • [35] Ki67 cytoplasmic expression
    Ciulla, Michele M.
    Acquistapace, Giulia
    Toffetti, Laura
    Paliotti, Roberta
    Ferrero, Stefano
    Magrini, Fabio
    Braidotti, Paola
    CELL CYCLE, 2009, 8 (13) : 2125 - 2125
  • [36] Ki67 and breast cancer mortality in women with invasive breast cancer
    Probert, Jake
    Dodwell, David
    Broggio, John
    Charman, Jackie
    Dowsett, Mitch
    Kerr, Amanda
    McGale, Paul
    Taylor, Carolyn
    Darby, Sarah C.
    Mannu, Gurdeep S.
    JNCI CANCER SPECTRUM, 2023, 7 (05)
  • [37] Breast Density, Ki67 and Larger Extensions of Breast Cancer
    Mameri, C.
    Sobral, L.
    Chambo, D.
    Totola, H.
    Mameri Filho, J.
    CANCER RESEARCH, 2009, 69 (24) : 836S - 837S
  • [38] Prognosis related to Ki67 in early breast cancer.
    Gerson, R.
    Alban, F.
    Villalobos, A.
    Serrano, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Ki67 expression in triple negative and luminal A breast cancer
    Sullu, Y.
    Demirag, G. G.
    Ozen, N.
    VIRCHOWS ARCHIV, 2011, 459 : S81 - S82
  • [40] Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
    Yuan, Jing Ping
    Wang, Lin Wei
    Qu, Ai Ping
    Chen, Jia Mei
    Xiang, Qing Ming
    Chen, Chuang
    Sun, Sheng-Rong
    Pang, Dai-Wen
    Liu, Juan
    Li, Yan
    PLOS ONE, 2015, 10 (04):
12345